Accessibility Menu
Arrow-Thin-Down
S&P 500
6,834.50
+0.9%
+59.74
Arrow-Thin-Down
DJI
48,134.89
+0.4%
+183.04
Arrow-Thin-Down
NASDAQ
23,307.62
+1.3%
+301.26
Arrow-Thin-Down
Bitcoin
$89,790.00
+1.3%
+$1,159.97
Arrow-Thin-Down
NKE
$58.71
-10.5%
-$6.92
Arrow-Thin-Down
CRWV
$83.00
+22.6%
+$15.32
Arrow-Thin-Down
RIVN
$22.45
+10.7%
+$2.17
Arrow-Thin-Down
FCEL
$8.34
-13.5%
-$1.30
Arrow-Thin-Down
RKLB
$70.52
+17.7%
+$10.60
Arrow-Thin-Down
CCL
$31.12
+9.8%
+$2.78
Arrow-Thin-Down
AMZN
$227.35
+0.3%
+$0.59
Arrow-Thin-Down
GOOG
$308.61
+1.6%
+$4.86
Arrow-Thin-Down
META
$659.30
-0.8%
-$5.15
Arrow-Thin-Down
MSFT
$485.06
+0.2%
+$1.08
Arrow-Thin-Down
NVDA
$180.76
+3.8%
+$6.62
Arrow-Thin-Down
TSLA
$481.15
-0.5%
-$2.22
Daily Stock GainersDaily Stock LosersMost Active Stocks
Editas Medicine Stock Quote

Editas Medicine (NASDAQ: EDIT)

$2.35
(0.0%)
+0.00
Price as of December 19, 2025, 3:58 p.m. ET

KEY DATA POINTS

Current Price
$2.34
Daily Change
(0.0%) +$0.00
Day's Range
$2.34 - $2.46
Previous Close
$2.34
Open
$2.37
Beta
2.08
Volume
9,214
Average Volume
2,469,266
Sector
Health Care
Market Cap
228.4M
Market Cap / Employee
$2.34M
52wk Range
$0.91 - $4.54
Revenue
-
Gross Margin
0.87%
Dividend Yield
N/A
EPS
-$2.38
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Editas Medicine Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
EDIT+74.63%-96.37%-48.43%-87%
S&P+16.49%+84.25%+12.99%+257%

Editas Medicine Company Info

Editas Medicine is a pioneer in gene editing technology. The biotech holds exclusive rights to CRISPR, a mechanism for cutting and pasting changes to DNA at precise locations.

News & Analysis

The Fool has written over 100 articles on Editas Medicine.
Featured Article

Why Editas Medicine Stock Was Skyrocketing This Week

The company's CEO made quite the encouraging statement regarding its immediate future.

Eric Volkman  |  Aug 15, 2025
Featured Article

Can This Beaten-Down Stock Bounce Back?

This small-cap biotech is seeking to develop breakthrough therapies, but so far it's found little success.

Prosper Junior Bakiny  |  Aug 12, 2025

Financial Health

General

Q3 2025YOY Change
Revenue$7.54M12265.6%
Gross Profit$6.82M543.6%
Gross Margin90.44%2611.8%
Market Cap$312.02M10.9%
Market Cap / Employee$1.27M0.0%
Employees246-7.2%
Net Income-$25.12M59.6%
EBITDA-$23.83M62.8%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q3 2025YOY Change
Net Cash$165.65M72.9%
Accounts Receivable$8.13M6352.4%
Inventory00.0%

Liabilities

Q3 2025YOY Change
Long Term Debt$67.63M206.1%
Short Term Debt$11.09M-32.4%

Ratios

Q3 2025YOY Change
Return On Assets-75.51%-24.9%
Return On Invested Capital-62.44%-21.3%

Cash Flow

Q3 2025YOY Change
Free Cash Flow-$31.28M43.7%
Operating Free Cash Flow-$30.84M41.3%

Valuation

MetricQ4 2024Q1 2025Q2 2025Q3 2025YoY Change
Price to Book0.600.712.9515.80886.14%
Price to Sales3.252.694.776.7447.98%
Price to Tangible Book Value0.600.712.9515.80886.13%
Enterprise Value to EBITDA3.942.80-3.60-9.471009.90%
Return on Equity-98.1%-140.8%-188.6%-211.4%169.06%
Total Debt$35.03M$31.13M$77.81M$78.72M104.53%

No results found

No transcripts available.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services